Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From KEDI Global Longevity Bio Index (KGLB)
5/29/2026, 12:00:00 AM
Announced positive Phase 3 SUCCESSOR-2 trial results on 2026-05-29 showing a 52% reduction in disease progression risk for multiple myeloma. This breakthrough is estimated to have a >10% price impact expected.
Korean Translation
2026년 5월 29일, 다발성 골수종 환자의 질병 진행 위험을 52% 감소시킨 3상 SUCCESSOR-2 임상 결과를 발표함. 획기적인 임상 결과로 10% 이상의 주가 영향이 예상됨.
Related Recent Events
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for a decision on the approval of the seasonal flu vaccine candidate (mRNA-1010) is scheduled for 2026-08-05, which is estimated to cause a ≥5% price impact scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 earnings results on July 30, 2026, expected.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
GSK plc (GSK) · Earnings Release
GSK's second quarter 2026 earnings release scheduled. Routine earnings releases typically result in a price impact of approximately 1-3%.
7/28/2026, 12:00:00 AM
Revvity Inc (RVTY) · Earnings Release
Revvity's Q2 2026 earnings release is scheduled for 2026-07-27.
7/27/2026, 12:00:00 AM